Global Nasopharyngeal Cancer Market Research and Forecast, 2018-2023
The nasopharynx is the upper part of the throat (pharynx) that lies behind the nose. The nasopharynx cancer or nasopharyngeal carcinoma (NPC) results from abnormal growth of cells in the nasopharynx. It is one of the rare cancer forms globally, ranking as the 27th most frequently diagnosed cancer globally in 2015. The market is expected to show a lucrative market growth rate. Increasing incidence of nasopharyngeal cancer across the globe high tobacco and alcohol consumption are the major factor driving the market during the forecasted period. As per the American Medical Association, the global incident cases of nasopharyngeal cancer in 2015 were more than 123,000 with a growth of 16.5% as compared to 2005. The prevalence of the cancer is in both male and female however male has more prevalence rate. There were 88,000 cases among men in 2015 with an incidence rate of 2.6 per 100,000 whereas it was 35,000 in women with an incidence rate of 0.9 per 100,000. Death rate per 100,000 were 1.4 in men and 0.5 in female. Furthermore, high intake of salt-preserved food and exposure to Epstein-Barr Virus (EBV) are also motivating the market. Almost all people infected with NPC have an infection by EBV virus in their blood. Infection with EBV is very common globally, often occurring in childhood. However, as per the American Cancer Society, the link between EBV infection and NPC is complex and it is not completely understood.
There are certain factors that are hindering the growth of the market. The high cost of treatment, low awareness toward cancer and an adverse side effect of treatment are the major restraint of the market. Alcohol and Tabaco consumption are the major cause for NPC however as per American Society of Clinical Oncology about 70% of Americans didn’t know that drinking alcohol is a risk factor for cancer. As per the National Center for Biotechnology Information, the cost of treatment of NPC range from $15,000 to $18,000.
The nasopharyngeal cancer market is studied critically by segmenting the market on the basis of cancer type, therapy and by diagnosis method. Mainly there are 3 types of nasopharyngeal cancer that are keratinising squamous cell carcinoma, non-keratinising squamous cell carcinoma, and undifferentiated carcinomas. It is estimated that non-keratinising squamous cell carcinoma will have a major market share in the forecasted period. According to the Canadian Cancer Society, non-keratinising squamous cell carcinoma have 60% share in total NPC. There are two types of diagnosis method. At the initial stage, NPC can be diagnosis by nasendoscopy, panendoscopy, and needle biopsy. For advance diagnosis, CT scan, pet scan, MRI scan, bone scan. A biopsy is estimated to have major market share during 2018-2023. By therapy, the market is divided into chemotherapy, immunotherapy, radiation therapy, and surgery. Radiation therapy is expected to have a major market share in during 2018-2023 as it is the most common treatment. Chemotherapy along with radiation therapy is also expected to use in the near future as it provides better treatment. It is known as chemoradiation.
The global nasopharyngeal cancer market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The market has been segmented into North America, Europe, Asia Pacific and Rest of the World. The Asia Pacific is expected to dominate in the global nasopharyngeal cancer market owing to the high prevalence of nasopharyngeal cancer in South China. This type of cancer is observed in the special ethnicity in China. This cancer is more common in China. According to the Center for Health Protection of Government of Hong Kong in 2015, NPC was the 6th common cancer in men and 14th in women. Large customer base, the continuous increment in economy and healthcare facility are the major factor for the growth of the market in the region. In the financial budget of 2018, the government of India has introduced a national health protection scheme to cover 500 million people by providing them up to $8000 per family per year for secondary and tertiary care hospitalization. It is also expected to raise the healthcare market in the country.
After the Asia Pacific, North America is expected to lead the market in the near future. According to the American Cancer Society, about 3,200 cases were registered in the US in 2015. Near to half of the people with NPC in the US are under 55 years age group. The prevalence is increasing due to increasing consumption of alcohol, Tabaco and another harmful element. Hence, it is also expected to show a significant growth rate. Europe is expected to show a lucrative growth rate during the forecasted period. In the UK the registered NPC cases were near to 250 on yearly basis.
A number of large pharmaceutical companies are active in nasopharyngeal cancer market. The major companies active in the market are Biodiem Ltd, Bristol-Myers Squibb, Cyclacel Pharmaceuticals, Eli Lilly, Glaxosmithkline, Merck & Co., Novartis International, Ono Pharmaceutical., Safoni, Theravectys and so on. Apart from this, numerous companies are manufacturing generic drugs for cancer which are used in chemotherapy and radiation therapy. Some are GE Healthcare, AstraZeneca, Roche and so on. The companies are focusing on product innovations, expansions, M&A, finding new market or innovate in their core competency in order to expand individual market share. Almost every oncology company have clinical trial products for NPC. As an instance, Merck has pembrolizumab or MK-3475 under the clinical trial as a treatment in nasopharyngeal cancer. The medicine has been already FDA-approved for use in certain types of cancer.
The report covers
There are certain factors that are hindering the growth of the market. The high cost of treatment, low awareness toward cancer and an adverse side effect of treatment are the major restraint of the market. Alcohol and Tabaco consumption are the major cause for NPC however as per American Society of Clinical Oncology about 70% of Americans didn’t know that drinking alcohol is a risk factor for cancer. As per the National Center for Biotechnology Information, the cost of treatment of NPC range from $15,000 to $18,000.
The nasopharyngeal cancer market is studied critically by segmenting the market on the basis of cancer type, therapy and by diagnosis method. Mainly there are 3 types of nasopharyngeal cancer that are keratinising squamous cell carcinoma, non-keratinising squamous cell carcinoma, and undifferentiated carcinomas. It is estimated that non-keratinising squamous cell carcinoma will have a major market share in the forecasted period. According to the Canadian Cancer Society, non-keratinising squamous cell carcinoma have 60% share in total NPC. There are two types of diagnosis method. At the initial stage, NPC can be diagnosis by nasendoscopy, panendoscopy, and needle biopsy. For advance diagnosis, CT scan, pet scan, MRI scan, bone scan. A biopsy is estimated to have major market share during 2018-2023. By therapy, the market is divided into chemotherapy, immunotherapy, radiation therapy, and surgery. Radiation therapy is expected to have a major market share in during 2018-2023 as it is the most common treatment. Chemotherapy along with radiation therapy is also expected to use in the near future as it provides better treatment. It is known as chemoradiation.
The global nasopharyngeal cancer market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. The market has been segmented into North America, Europe, Asia Pacific and Rest of the World. The Asia Pacific is expected to dominate in the global nasopharyngeal cancer market owing to the high prevalence of nasopharyngeal cancer in South China. This type of cancer is observed in the special ethnicity in China. This cancer is more common in China. According to the Center for Health Protection of Government of Hong Kong in 2015, NPC was the 6th common cancer in men and 14th in women. Large customer base, the continuous increment in economy and healthcare facility are the major factor for the growth of the market in the region. In the financial budget of 2018, the government of India has introduced a national health protection scheme to cover 500 million people by providing them up to $8000 per family per year for secondary and tertiary care hospitalization. It is also expected to raise the healthcare market in the country.
After the Asia Pacific, North America is expected to lead the market in the near future. According to the American Cancer Society, about 3,200 cases were registered in the US in 2015. Near to half of the people with NPC in the US are under 55 years age group. The prevalence is increasing due to increasing consumption of alcohol, Tabaco and another harmful element. Hence, it is also expected to show a significant growth rate. Europe is expected to show a lucrative growth rate during the forecasted period. In the UK the registered NPC cases were near to 250 on yearly basis.
A number of large pharmaceutical companies are active in nasopharyngeal cancer market. The major companies active in the market are Biodiem Ltd, Bristol-Myers Squibb, Cyclacel Pharmaceuticals, Eli Lilly, Glaxosmithkline, Merck & Co., Novartis International, Ono Pharmaceutical., Safoni, Theravectys and so on. Apart from this, numerous companies are manufacturing generic drugs for cancer which are used in chemotherapy and radiation therapy. Some are GE Healthcare, AstraZeneca, Roche and so on. The companies are focusing on product innovations, expansions, M&A, finding new market or innovate in their core competency in order to expand individual market share. Almost every oncology company have clinical trial products for NPC. As an instance, Merck has pembrolizumab or MK-3475 under the clinical trial as a treatment in nasopharyngeal cancer. The medicine has been already FDA-approved for use in certain types of cancer.
The report covers
- Comprehensive research methodology of global nasopharyngeal cancer market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global nasopharyngeal cancer market.
- Insights about market determinants which are stimulating the global nasopharyngeal cancer market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
1. REPORT SUMMARY
1.1. Research Methods and Tools
1.2. Pipeline Analysis
1.3. Market Breakdown
1.3.1. By Segments
1.3.2. By Geography
1.3.3. By Stakeholders
1.3.4. Exceptions
2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Patent Analysis
2.3. Analyst Insights & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendation
2.3.3. Conclusion
2.4. Regulation
2.4.1.1. United States
2.4.1.2. European Union
2.4.1.3. China
2.4.1.4. India
3. MARKET DETERMINANT
3.1. Motivators
3.1.1. Increasing Incidence of Nasopharyngeal Cancer
3.1.2. High Tobacco and Alcohol Consumption
3.1.3. High Intake of Salt Preserved Food
3.1.4. Exposure to Epstein-Barr Virus (EBV)
3.2. Restraints
3.2.1. High Cost of Treatment
3.2.2. Low Awareness Toward Cancer
3.2.3. Adverse Effect of Treatment
3.3. Opportunities
3.3.1. Rapid Adoption of Technologies in Healthcare Premises
4. MARKET SEGMENTATION
4.1. Global Nasopharyngeal Cancer Market, By Cancer Type
4.1.1. Keratinising Squamous Cell Carcinoma
4.1.2. Non-Keratinising Squamous Cell Carcinoma
4.1.3. Undifferentiated Carcinomas
4.1.4. Other (Adenocarcinoma and Adenoid Cystic Carcinomas)
4.2. Global Nasopharyngeal Cancer Market, By Diagnosis Method
4.2.1. Initial Diagnosis
4.2.1.1. Nasendoscopy
4.2.1.2. Panendoscopy
4.2.1.3. Fine Needle Aspiration/Needle Biopsy
4.2.2. Advanced Diagnosis
4.2.2.1. CT Scan
4.2.2.2. PET Scan
4.2.2.3. MRI Scan
4.2.2.4. Bone Scan
4.3. Global Nasopharyngeal Cancer Market, By Therapy
4.3.1. Chemotherapy
4.3.2. Immunotherapy
4.3.3. Surgery
4.3.4. Targeted Therapy
5. COMPETITIVE LANDSCAPE
5.1. Key Strategies
5.2. Key Company Analysis
6. REGIONAL ANALYSIS
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.3. APAC
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of APAC
6.4. Rest of The World
7. COMPANY PROFILES
7.1. Biodiem Ltd.
7.2. Bristol-Myers Squibb
7.3. Cyclacel Pharmaceuticals Inc.
7.4. Eli Lilly And Co.
7.5. GlaxoSmithKline Plc.
7.6. Merck & Co., Inc.
7.7. Novartis International AG
7.8. Ono Pharmaceutical Co.,
7.9. Safoni
7.10. Theravectys SA
1.1. Research Methods and Tools
1.2. Pipeline Analysis
1.3. Market Breakdown
1.3.1. By Segments
1.3.2. By Geography
1.3.3. By Stakeholders
1.3.4. Exceptions
2. MARKET OVERVIEW AND INSIGHTS
2.1. Definition
2.2. Patent Analysis
2.3. Analyst Insights & Current Market Trends
2.3.1. Key Findings
2.3.2. Recommendation
2.3.3. Conclusion
2.4. Regulation
2.4.1.1. United States
2.4.1.2. European Union
2.4.1.3. China
2.4.1.4. India
3. MARKET DETERMINANT
3.1. Motivators
3.1.1. Increasing Incidence of Nasopharyngeal Cancer
3.1.2. High Tobacco and Alcohol Consumption
3.1.3. High Intake of Salt Preserved Food
3.1.4. Exposure to Epstein-Barr Virus (EBV)
3.2. Restraints
3.2.1. High Cost of Treatment
3.2.2. Low Awareness Toward Cancer
3.2.3. Adverse Effect of Treatment
3.3. Opportunities
3.3.1. Rapid Adoption of Technologies in Healthcare Premises
4. MARKET SEGMENTATION
4.1. Global Nasopharyngeal Cancer Market, By Cancer Type
4.1.1. Keratinising Squamous Cell Carcinoma
4.1.2. Non-Keratinising Squamous Cell Carcinoma
4.1.3. Undifferentiated Carcinomas
4.1.4. Other (Adenocarcinoma and Adenoid Cystic Carcinomas)
4.2. Global Nasopharyngeal Cancer Market, By Diagnosis Method
4.2.1. Initial Diagnosis
4.2.1.1. Nasendoscopy
4.2.1.2. Panendoscopy
4.2.1.3. Fine Needle Aspiration/Needle Biopsy
4.2.2. Advanced Diagnosis
4.2.2.1. CT Scan
4.2.2.2. PET Scan
4.2.2.3. MRI Scan
4.2.2.4. Bone Scan
4.3. Global Nasopharyngeal Cancer Market, By Therapy
4.3.1. Chemotherapy
4.3.2. Immunotherapy
4.3.3. Surgery
4.3.4. Targeted Therapy
5. COMPETITIVE LANDSCAPE
5.1. Key Strategies
5.2. Key Company Analysis
6. REGIONAL ANALYSIS
6.1. North American
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Spain
6.2.4. France
6.2.5. Italy
6.3. APAC
6.3.1. India
6.3.2. China
6.3.3. Japan
6.3.4. Rest of APAC
6.4. Rest of The World
7. COMPANY PROFILES
7.1. Biodiem Ltd.
7.2. Bristol-Myers Squibb
7.3. Cyclacel Pharmaceuticals Inc.
7.4. Eli Lilly And Co.
7.5. GlaxoSmithKline Plc.
7.6. Merck & Co., Inc.
7.7. Novartis International AG
7.8. Ono Pharmaceutical Co.,
7.9. Safoni
7.10. Theravectys SA
LIST OF TABLES
TABLE # 1 GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 2 GLOBAL KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL NON-KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL UNDIFFERENTIATED CARCINOMAS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL OTHER NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL NASOPHARYNGEAL CANCER MARKET, BY DIAGNOSIS METHOD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL INITIAL NASOPHARYNGEAL CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL NASENDOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL PANENDOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL NASOPHARYNGEAL CANCER NEEDLE BIOPSY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL ADVANCED DIAGNOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL NASOPHARYNGEAL CANCER CT SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL NASOPHARYNGEAL CANCER PET SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL NASOPHARYNGEAL CANCER MRI SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 15 GLOBAL NASOPHARYNGEAL CANCER CHEST X-RAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 16 GLOBAL NASOPHARYNGEAL CANCER BONE SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 17 GLOBAL NASOPHARYNGEAL CANCER MARKET, BY THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 18 GLOBAL NASOPHARYNGEAL CANCER CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 19 GLOBAL NASOPHARYNGEAL CANCER IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 20 GLOBAL NASOPHARYNGEAL CANCER CHEMORADIOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 21 GLOBAL NASOPHARYNGEAL CANCER SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 22 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 23 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
TABLE # 24 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY METHOD 2017-2023 ($ MILLION)
TABLE # 25 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
TABLE # 26 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 27 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
TABLE # 28 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY METHOD 2017-2023 ($ MILLION)
TABLE # 29 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
TABLE # 30 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 31 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
TABLE # 32 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY METHOD 2017-2023 ($ MILLION)
TABLE # 33 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
TABLE # 1 GLOBAL NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 2 GLOBAL KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 3 GLOBAL NON-KERATINISING SQUAMOUS CELL CARCINOMA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 4 GLOBAL UNDIFFERENTIATED CARCINOMAS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 5 GLOBAL OTHER NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 6 GLOBAL NASOPHARYNGEAL CANCER MARKET, BY DIAGNOSIS METHOD MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 7 GLOBAL INITIAL NASOPHARYNGEAL CANCER DIAGNOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 8 GLOBAL NASENDOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 9 GLOBAL PANENDOSCOPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 10 GLOBAL NASOPHARYNGEAL CANCER NEEDLE BIOPSY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 11 GLOBAL ADVANCED DIAGNOSIS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 12 GLOBAL NASOPHARYNGEAL CANCER CT SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 13 GLOBAL NASOPHARYNGEAL CANCER PET SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 14 GLOBAL NASOPHARYNGEAL CANCER MRI SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 15 GLOBAL NASOPHARYNGEAL CANCER CHEST X-RAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 16 GLOBAL NASOPHARYNGEAL CANCER BONE SCAN MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 17 GLOBAL NASOPHARYNGEAL CANCER MARKET, BY THERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 18 GLOBAL NASOPHARYNGEAL CANCER CHEMOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 19 GLOBAL NASOPHARYNGEAL CANCER IMMUNOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 20 GLOBAL NASOPHARYNGEAL CANCER CHEMORADIOTHERAPY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 21 GLOBAL NASOPHARYNGEAL CANCER SURGERY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE # 22 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 23 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
TABLE # 24 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY METHOD 2017-2023 ($ MILLION)
TABLE # 25 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
TABLE # 26 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 27 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
TABLE # 28 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY METHOD 2017-2023 ($ MILLION)
TABLE # 29 EUROPE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
TABLE # 30 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY CANCER TYPE, 2017-2023 ($ MILLION)
TABLE # 31 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY DIAGNOSIS METHOD 2017-2023 ($ MILLION)
TABLE # 32 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY THERAPY METHOD 2017-2023 ($ MILLION)
TABLE # 33 ASIA PACIFIC NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, BY COUNTRIES 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE # 1 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY CANCER TYPE, 2017-2023 ($ MILLION)
FIGURE # 2 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY DIAGNOSTIC METHOD 2017-2023 ($ MILLION)
FIGURE # 3 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY THERAPY 2017-2023 ($ MILLION)
FIGURE # 4 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY GEOGRAPHY, 2017-2023 ($ MILLION)
FIGURE # 5 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET SHARE 2017-2023($ MILLION)
FIGURE # 6 UNITED STATES NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 7 CANADA MARKET NASOPHARYNGEAL CANCER RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 8 EUROPE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
FIGURE # 9 UK NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 10 GERMANY NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 11 SPAIN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 12 FRANCE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 13 ITALY NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 14 ROE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 15 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
FIGURE # 16 CHINA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 17 INDIA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 18 JAPAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 19 REST OF ASIA PACIFIC (ROAPAC) NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 20 REST OF WORLD (ROW)NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 1 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY CANCER TYPE, 2017-2023 ($ MILLION)
FIGURE # 2 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY DIAGNOSTIC METHOD 2017-2023 ($ MILLION)
FIGURE # 3 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY THERAPY 2017-2023 ($ MILLION)
FIGURE # 4 GLOBAL NASOPHARYNGEAL CANCER MARKET SHARE, BY GEOGRAPHY, 2017-2023 ($ MILLION)
FIGURE # 5 NORTH AMERICA NASOPHARYNGEAL CANCER MARKET SHARE 2017-2023($ MILLION)
FIGURE # 6 UNITED STATES NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 7 CANADA MARKET NASOPHARYNGEAL CANCER RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 8 EUROPE MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
FIGURE # 9 UK NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 10 GERMANY NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 11 SPAIN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 12 FRANCE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 13 ITALY NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 14 ROE NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 15 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION)
FIGURE # 16 CHINA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 17 INDIA NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 18 JAPAN NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 19 REST OF ASIA PACIFIC (ROAPAC) NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE # 20 REST OF WORLD (ROW)NASOPHARYNGEAL CANCER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
